BACKGROUND
Contrast enhancement is generally considered an adverse prognostic feature in adult glioma. However, its significance in newly diagnosed grade 2 IDH-mutant glioma remains uncertain, with important implications for use of the mutant IDH inhibitor vorasidenib. We evaluated survival outcomes associated with pre...
Vihang Nakhate, Aleksandra B. Lasica, Loai Aker et al.· Neuro-Oncology· 0 citations
Abstract Background Life expectancy for cancer patients has improved due to new therapies, but many survivors experience long-lasting side effects, including cancer-related cognitive impairment (CRCI). CRCI symptoms—such as difficulties with attention, memory, processing speed, fatigue, and concentration—can persist fo...
A. Benelli, Julianne Reilly, Jorge Ortega-Márquez et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.